Trevi Advances Phase 3 Programs, Extends Cash Runway; Thesis Shifts to Neutral

What happened

Trevi Therapeutics initiated its second Phase 3 OCEAN trial for IPF-related chronic cough in Q3 2026, with both OCEAN trials now actively recruiting, and held a positive FDA meeting on non-IPF ILD chronic cough that paves the way for a Phase 2 dose-ranging trial expected to start in Q1 2027. The company also received a Notice of Allowance from the USPTO for a patent covering nalbuphine ER dosing in hepatically impaired patients with non-IPF ILD cough, extending IP protection to 2041. Management announced that cash runway now extends into 2030, funding key clinical milestones without immediate dilution risk. These developments directly address two prior concerns from our analysis: regulatory design uncertainty for IPF chronic cough and funding sufficiency for multiple late-stage programs. While execution risk has diminished, the investment case still hinges on Phase 3 efficacy and safety outcomes, and the market may already reflect much of this progress, keeping risk/reward balanced.

Implication

Trevi has de-risked the regulatory and funding aspects of its development plan, shifting the focus squarely to clinical outcomes. The initiation of both Phase 3 OCEAN trials suggests the FDA accepted the trial design, reducing the probability of a costly pivot. The extended cash runway into 2030 removes near-term financing overhang, allowing the company to reach key data readouts without dilution. However, the stock is still a single-asset story, and positive Phase 2 results do not guarantee Phase 3 success, so asymmetric risk remains. For investors, this justifies a neutral-to-hold stance: maintain existing positions with a tighter stop, but avoid adding aggressively unless the stock pulls back to levels that better compensate for binary clinical risk.

Thesis delta

Previously we rated TRVI a Potential Sell with a trim above $15 due to regulatory and funding uncertainties. With Phase 3 OCEAN trials initiated and recruiting, positive FDA feedback on non-IPF ILD cough, and cash runway extended to 2030, those concerns have been substantially mitigated. We now view the stock as a Hold, with improved risk/reward, but still await Phase 3 data before turning constructive.